, Natalino Hagime Yoshinari 5 Lyme disease (LD) is a multifaceted infectious disease 1 caused by Borrelia burgdorferi sensu lato spirochetes, which are transmitted to humans by tick bites in at-risk areas in the Northern hemisphere 2, 3 . Since this microorganism is difficult to culture, the disease is usually diagnosed by serological tests 3 . The most common neurological presentations of LD are meningitis, cranial neuritis, and radiculoneuritis 4 . Brazilian Lyme-disease-like illness (BLDLI) or BaggioYoshinari syndrome (BYS) is a unique zoonosis found in Brazil. It reproduces all clinical symptoms of LD except for the high frequencies of relapse and the presence of autoimmune manifestations [5] [6] [7] . The vector of BLDLI belongs to genera Amblyomma and Rhipicephalus rather than to the Ixodes ricinus complex, which is responsible for transmission in the Northern hemisphere 6, 8, 9 . To date, the etiologic agent has not been isolated or cultured in Brazil. However, electron microscopy analysis of patients' blood samples showed microorganisms resembling spirochetes with atypical morphologies 5 . Recently, a polymerase chain reaction (PCR) analysis carried out with primers derived from the flgE gene has proven that Brazilian zoonosis is caused by microorganisms from Borrelia Two cases of neuroborreliosis associated with unremitting headache, which is a symptom associated with late-stage BLDLI, are presented herein. This symptom can be unnoticed or misdiagnosed by Brazilian physicians due to its difficult diagnosis and late appearance in the course of the disease.
CAse rePorts

Case 1
A 44-year-old female dentist whose migraine without aura was controlled in the previous year with atenolol 25 mg one day (QD), presented in November 2009 due to worsening of her headaches. Previous medical consultations had identified benign postural vertigo, symptomatic cervical disk herniation, allergic rhinitis, hiatal hernia, saphenectomy, and hysterectomy. The patient reported that her first headache attacks due to BLDLI were quite similar to her previous migraine ones and responded well to the use of over-the-counter (OTC) drugs (simple analgesic drugs and/or nonsteroidal anti-inflammatory drugs -NSAIDs).
After six months, when the diagnosis of Lyme-like disease was concluded, her headaches were occurring daily without any respite and were no longer responsive to simple analgesic drugs, NSAIDs, or anti-migraine drugs such as dihydroergotamine (DHE) or triptans. The patient also stated that the headaches were accompanied by anorexia, nausea, disequilibrium, and depressive mood. In the patient's own words: "it was just like having migraine and labyrinthitis together, but on a larger scale. " The participant also reported that at that time, she was experiencing a decrease in the quality of her sleep and waking up tired. Atenolol was withdrawn, and methysergide and trazodone were started without success. Meanwhile, she consulted a dermatologist because of a skin lesion in her left groin, which was diagnosed as erythema migrans (EM). A review of her history revealed that she had been having some dizziness and minor joint and ankle pains. She denied history of tick bites but said that recently, during her vacations, she had worked in a mission in Northern Brazil, a known risk area for BLDLI. The brain magnetic resonance imaging (MRI) revealed a small hyperintense lesion in the head of the left caudate nucleus (Figure) and a bilaterally delayed P100 latency in her visual evoked responses. Her cerebrospinal fluid (CSF) examination was normal. Serology for B. burgdorferi was performed at LIM-17 HCFMUSP and was positive (WB: IgG, two bands; IgM, one band). The patient received intravenous ceftriaxone 2 g one day (QD) for 30 days and then doxycycline 100 mg twice a day (BID) for three months. Her frequent headaches and dizziness had already abated when she was receiving intravenous therapy, but the joint pains remitted only after sulphasalazine 1 g BID and hydroxychloroquine 400 mg QD had been added.
In February 2011, the woman had a recurrence of EM (a secondary annular skin lesion) on her left ankle, and doxycycline 100 mg BID for three months was restarted. A control MRI revealed that the left caudate lesion had been solved. In July 2011 topiramate 25 mg BID was started for her continuing migraines, and trazodone was reintroduced for her disturbed sleep. In November 2011, she started a new course of ceftriaxone because of bilateral retinal lesion.
Case 2
A 40-year-old female presented in April 2011 with intractable headaches. She had had sporadic nondisabling headaches since her twenties, but at the age of 37 (in 2008) her attacks increased in frequency and intensity and became disabling. The headaches were bilateral, pressure-like or throbbing with a temporo-parieto-occipital distribution, being stronger in the occipital region. The pain would reach a tenpoint intensity on a ten-point verbal pain scale with dizziness. Attacks were accompanied by nausea and intense osmophobia, but not by photophobia or phonophobia. They did not happen at any specific time, and occurred up to twice a week. They lasted from 24 to 72 hours, sometimes starting early in the morning and getting worse in the evening.
Her medical history revealed a sequela of toxoplasmosis in her left eye, intermittent vertigo, allergic rhinitis, gastroesophageal reflux, cervical disk herniation, femoral dysplasia, and three pregnancies (two until term and one spontaneous abortion). She had also had an EM lesion over her left shoulder in 2005 and bilateral knee pains starting thereafter. Her neurological examination was unremarkable. The brain MRI was normal, as was the CSF fluid examination. Serology for antibodies to B. burgdorferi was performed at LIM-17 HCFMUSP and proved to be positive WB (IgG, one band; IgM, two bands), satisfying the Brazilian Reference Center's standard criteria for diagnosis of Brazilian borreliosis. Because of her past history of EM and arthritis, BLDLI was diagnosed and treated with intravenous ceftriaxone 2 g QD for 30 days followed by doxycycline 100 mg BID for three months. Her frequent headaches, dizziness, and knee pains abated at the beginning of intravenous ceftriaxone therapy and had not recurred at the time of writing. However, she was placed on atenolol and flunarizine for the infrequent migraine headaches. She continued to have mild sporadic bitemporal headaches, which got worse in the evening. Also, she did not have any associated symptoms, and these were enhanced by heat and occurred twice a month.
DIsCussIoN
BLDLI, also known as BYS, is a new zoonosis described in Brazil. It differs from LD in that to date its etiological agent has not been isolated, its vector does not belong to the Ixodes ricinus complex, and its clinical symptoms are often recurrent 6, 10, 11 . Researchers from LIM-17 HCFMUSP believe that geographic conditions and ecological biodiversity in Brazil favored the evolution of spirochetes with atypical morphologies adapted for survival in Brazilian vertebrate and invertebrate hosts 6 . Borrelias with atypical morphologies tend to survive inside host cells and become resistant to antibiotics and antibodies, explaining the occurrence of relapsing symptoms and low immune reactivity to B. burgdorferi sensu lato antigens 5, [9] [10] [11] . These BLDLI peculiarities explain why Brazilian patients usually do not meet the Centers for Disease Control and Prevention (CDC) criteria for serologic diagnosis of LD.
In light of this, LIM-17 HCFMUSP established the following diagnostic criteria for recognizing most suspected cases of BLDLI in Brazil (Table1) 5 : epidemiology, clinical manifestations and serology (major criteria); and relapsing symptoms, chronic fatigue and/or cognitive disturbances and identification of spirochete-like microorganisms by dark field microscopy (minor criteria). A positive diagnosis is made if the results for three major criteria or two major and two minor criteria are positive.
Patients with BLDLI present with EM in nearly 50% of the cases. In the secondary stage of the disease, arthritis and neuropathy are observed in 35%, and cardiac manifestation in 5% 6 . Relapsing episodes are found in almost 75% of the situations when patients are diagnosed in the late stage of the disease (more than three months after disease onset) even after antibiotic treatment 6, 10, 11 . Both patients reported here came to the service with previous EM, arthritis, and positive serology for B. burgdorferi. Interestingly, patient 1 had recurrent skin lesion (secondary annular erythema) and bilateral retinal lesion even after antibiotic treatment, confirming that BLDLI has late relapsing symptoms. Shinjo et al. 11 studied 30 patients with neuropsychiatric symptoms related to BLDLI and found meningitis in 50% of their series, peripheral motor neuropathy in 40%, peripheral sensitive neuropathy in 33.3%, encephalitis/myelitis in 33%, facial palsy in 26.7%, ocular symptoms in 36.7%, dysacusis in 10%, dysarthria in 6.7%, dysphagia in 6.7%, and psychiatric symptoms in 20%. It is noteworthy that EM was reported by 43.3% of neurological patients and arthritis by 50%. Extended follow-up of some of them showed that 73.3% had recurrent symptoms. In addition, the frequency of skin lesions diminished as the disease progressed, making it very difficult to identify BLDLI in the late relapsing stage.
Treatment of BLDLI is also different from that recommended for LD. In the acute stage of the disease, doxycycline 100 mg twice a day for at least three weeks is recommended. If the disease is diagnosed more than three months after onset, continued treatment with the same substance for three months is recommended. If neurological symptoms are present, the use of ceftriaxone 2 g/day for one month with an additional three-month course of doxycycline is indicated.
Several types of headaches have been reported to be associated with LD 4, 12, 13, [15] [16] [17] [18] (Table 2) . In a large sample of confirmed LD patients, headache, orofacial, and dental pains were reported to be common complaints 12 . Migraine has been described in approximately half of inpatients with
